TxBEHNAnCOL

very best job precio diovan 320/25 ** Drugmaker Retrophin Inc on Wednesday said itoffered to buy the rest of Transcept Pharmaceuticals Inc shares it does not already own for $4 per share,valuing Transcept at about $75 million. Retrophin’s offerrepresents an 11 percent premium to Transcept’s closing shareprice of $3.59 on the Nasdaq on Wednesday.

Schreibe einen Kommentar

*

code